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Abstract The Spot method of multiple peptide synthesis was
used to map in a systematic manner regions of the human cardiac
troponin I sequence (hcTnI) involved in interactions with its
physiological partner, troponin C (cTnC). Ninety-six 20-mer
peptides describing the entire hcTnI sequence were chemically
assembled; their reactivity with [125I]cTnC, in the presence of
3 mM Ca2+, enabled the assignment of six sites of interaction
(residues 19^32, 45^54, 129^138, 145^164, 161^178 and 191^
210). For several sites, a good correlation with literature data
was obtained, thus validating this methodological approach.
Synthetic peptides, each containing in their sequence an
interaction site, were prepared. As assessed by BIACORE, all
of them exhibited an affinity for cTnC in the range of 1036^
1037 M, except for hcTnI [39^58] which showed a nanomolar
affinity. This peptide was also able to block the interaction
between hcTnI and cTnC. We therefore postulate that despite the
existence of multiple cTnC interaction sites on the hcTnI
molecule, only that region of hcTnI allows a stabilization of
the complex. Residues 19^32 from the N-terminal cardio-specific
extension of hcTnI were also found to be involved in interaction
with cTnC; residues 19^32 may correspond to the minimal
sequence of the extension which could switch between the N- and
C-terminal TnC domains, depending on its phosphorylation
state. Finally, two Ca2+-dependent cTnC binding domains within
the C-terminal part of hcTnI (residues 164^178 and 191^210)
were also mapped. The latter site may be linked with the cardiac
dysfunction observed in stunned myocardium. ß 2000 Federa-
tion of European Biochemical Societies. Published by Elsevier
Science B.V. All rights reserved.
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1. Introduction
Vertebrate skeletal and cardiac muscle contraction are regu-
lated in a Ca2-dependent manner by the troponin complex
through interactions with tropomyosin and the actin ¢lament.
The troponin complex consists of three proteins: troponin I
(TnI) which inhibits the actomyosin Mg2-ATPase, troponin
C (TnC) which binds Ca2 ions and removes TnI inhibition
and troponin T (TnT) which makes primary protein^protein
contacts with tropomyosin. Ca2 binding to TnC initiates
structural changes and alters protein^protein interactions,
leading to muscle contraction. Two isoforms of TnC exist in
striated muscle, fast skeletal TnC (sTnC) and slow skeletal,
which is identical to cardiac TnC (cTnC). The crystal struc-
ture of TnC reveals a dumbbell shaped molecule with its N-
and C-terminal domains well separated by a single central K
helix [1,2] and four Ca2 binding sites, two in each domain. In
cTnC, the Ca2 binding site I, located in the NH2-regulatory
domain, is naturally inactive. The cardiac TnI isoform has a
unique N-terminal extension of 32 residues which could be
phosphorylated mainly at serine residues 23 and 24 upon L-
adrenergic stimulation [3,4]. Compared to the skeletal iso-
form, much less is known about the regions of cardiac TnI
involved in the Ca2-dependent regulation. An antiparallel
arrangement between cTnC and cTnI has been proposed [5].
Consistent with this model, the N-terminal domain of cTnI
(residues 33^80) forms a stable binary complex with cTnC-
(81^161) [6], and cTnI-(147^163) has been shown to interact
with the NH2-domain of cTnC, stabilizing its open conforma-
tion [7]. An inhibitory region (residues 128^148 in human
cTnI) has been identi¢ed [8] and recent results from Rarick
[9] indicate that residues 152^199 of cTnI are essential for full
inhibitory activity and Ca2 sensitivity of myo¢brillar ATPase
activity in the heart.
In order to get a comprehensive view of the regions of
hcTnI involved in binding, we report here on the systematic
mapping of human cardiac TnI (hcTnI) regions that interact
with cTnC. Ninety-six 20-mer peptides describing the entire
hcTnI sequence were assembled by the Spot method [10].
Their reactivity with [125I]cTnC was assessed, leading to the
localization of six interaction sites. Soluble peptides, contain-
ing in their sequence an interaction motif, were synthesized
and their a⁄nity for cTnC was measured by surface plasmon
resonance analysis.
2. Materials and methods
2.1. Preparation of bovine cTnC
Bovine cTnC whose sequence is identical to the human protein was
used. TnC was obtained from deep-frozen bovine cardiac muscle and
puri¢ed as described by Thulin and Vogel [11]. The semi-puri¢ed
cTnC obtained was dialyzed against 10 mM Tris pH 7.5, 200 mM
NaCl, 3 mM CaCl2, 5 mM DTT bu¡er and puri¢ed by gel ¢ltration
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chromatography on Sephacryl HR100 (Pharmacia), previously equil-
ibrated with the same bu¡er. TnC was eluted as a single peak at 105
ml and stored until use at 380‡C. The purity of the protein was
monitored by sodium dodecyl sulfate polyacrylamide (12%) gel elec-
trophoresis. Protein concentration was determined by the Bradford
method (Bio-Rad, Munich, Germany).
2.2. Iodination of cTnC
Puri¢ed cTnC was radioiodinated by the Bolton and Hunter meth-
od [12], with 100 WCi of N-succinimidyl 3-(4-hydroxy,5-
[125I]iodophenyl)propionate (Amersham) per 100 Wg of cTnC. The
iodinated mixture was separated by gel ¢ltration chromatography
on a PD10 column (Pharmacia), using 10 mM Tris pH 7.5, 200
mM NaCl, 3 mM CaCl2, 5 mM DTT as eluent. The speci¢c activity
of the puri¢ed labelled cTnC was about 5U105 cpm/Wg. A control,
irrelevant, protein (an anti-carcinoembryonic antigen IgG) was la-
belled in similar conditions.
2.3. Biotinylation of cTnC
Puri¢ed cTnC was biotinylated according to the ECL protein bio-
tinylation module kit protocol (Amersham) with 40 Wl of biotinylation
reagent per mg of protein. The biotinylated mixture was separated on
a PD10 column as described above. Biotinylated cTnC was stored at
320‡C.
2.4. Peptide synthesis on cellulose membrane
Ninety-six overlapping 20-mer peptides frameshifted by two resi-
dues, representing the complete hcTnI protein sequence [13], were
synthesized on a cellulose membrane (Abimed GmbH, Langen¢eld,
Germany) by the Spot technique [10]. The synthesis was performed by
using an ASP 412 spotter (Abimed GmbH), as previously described
[14].
2.5. Reactivity of cellulose-bound peptides
The set of membrane bound peptides was incubated for 90 min at
37‡C with either [125I]TnC (55.5 nM; 5.3U105 cpm/ml) or an equiv-
alent amount of [125I]IgG, as a control. The binding of radiolabelled
proteins to cellulose-bound peptides was detected by autoradiography
of the membrane. The membrane was further treated so as to remove
bound protein as described [10] and reused when necessary.
2.6. Synthesis of soluble hcTnI peptides
Peptides were prepared by Fmoc solid-phase synthesis on a AMS
422 robot (Abimed Gmbh) [15] as described [14]. Phosphorylated
serine (Sp) was from Novabiochem as well as other Fmoc amino
acids. Synthetic peptides corresponding to regions of interaction
with cTnC were as follows:hcTnI [15^34] (15APAPIRRRSSNY-
RAYATEPH34), hcTnI [15^34 diP] (15APAPIRRRSpSpNYR-
AYATEPH34), hcTnI [39^58] (39SKISASRKLQLKTLLLQIAK58),
hcTnI [124^143] (124EIADLTQKIFDLRGKFKRPT143), hcTnI
[145^164] (145RRVRISADAMMQALLGARAK164), hcTnI [159^178]
(159LGARAKESLDLRAHLKQVKK178) and hcTnI [191^210]
(191WRKNIDALSGMEGRKKKFES210). The following control pep-
tides (corresponding to non-binding regions of hcTnI) were also syn-
thesized: hcTnI [73^92] (73GRALSTRCQPLELTGLGFAE92), hcTnI
[89^108] (89GFFAELQDLCRQLHARVDKV108), and hcTnI [109^
128] (109EERYDIEAKVTKNITEIADL128).
2.7. Real-time interaction analysis by BIACORE
The binding of synthetic hcTnI peptides to immobilized cTnC was
measured by using BIACORE 2000 (Biacore AB, Uppsala, Sweden).
CTnC (50 Wg/ml in 10 mM acetate bu¡er) was coupled to a £owcell of
a CM5 sensor chip (Biacore AB) using the NHS-EDC protocol. The
amount of bound cTnC was 569 pg/mm2. The second £owcell was
treated with bu¡er and activating reagents alone and used as a con-
trol. Increasing concentrations of synthetic hcTnI peptides (0.5^80 Wg/
ml in 10 mM HEPES bu¡er, 3 mM Ca2 or 10 mM EDTA) were
injected onto the two £owcells and the sensorgrams corresponding to
the binding of peptides to cTnC and to the control were simultane-
ously registered: association time 120 s, dissociation time 300 s, £ow
rate 50 Wl/min. After subtraction of the background signal recorded
for the control £owcell, the binding level, resonance unit (RU) of each
peptide on cTnC was measured 6 s after the end of injection (126 s
total time). The KD constants were obtained from these sensorgrams,
using BIAevaluation 3.0 software (Biacore AB) and the global^global
or local^global method (simultaneous analysis of the sensorgrams
corresponding to respectively all or one peptide concentration). As a
control experiment, soybean trypsin inhibitor (a protein unrelated to
cTnC, but having a similar molecular weight and isoelectric point)
was coupled to a CM5 sensor chip and the binding of the peptide
having shown the best binding properties to cTnC was assessed.
2.8. Competitive enzyme-linked immunosorbent assay (ELISA) with
hcTnI peptides
Biotinylated cTnC (2.7 nM) was preincubated with synthetic pep-
tides derived from the hcTnI sequence at increasing concentrations
(2.7 nM^2.7 WM; molar excess 1^103) for 2.5 h at 4‡C in TBS (50
mM Tris, 150 mM NaCl, pH 7.5), 0.1% Tween 20, 1% BSA (blocking
solution) and 3 mM CaCl2. ELISA plates were coated with 100 Wl of
41.6 nM hcTnI (prepared as described [16]) overnight at 4‡C in PBS.
Plates were washed with PBS, 0.1% Tween and blocked for 90 min at
37‡C with blocking solution. The blocking solution was removed and
100 Wl of the mixture of cTnC with the synthetic peptides was added
to the wells. After incubation for 90 min at 37‡C and washing, bind-
ing of cTnC was detected by peroxidase-conjugated streptavidin
(Amersham) (diluted 1:3000 in blocking solution). After 60 min at
37‡C, and washing, color was developed by addition of 100 Wl per well
of o-phenylenediamine (4 mg/ml) containing 0.03% (v/v) hydrogen
peroxide in 0.1 M citrate bu¡er pH 5. The resulting absorbance was
measured at 450 nm with an automated microtiter plate reader (Dy-
natech MR 5000).
3. Results
3.1. Determination of the cardiac TnI regions involved in the
interaction with TnC
The capacity of peptides derived from the sequence of
hcTnI to bind cTnC was investigated in a systematic manner.
The entire 210 amino acid sequence of hcTnI was presented as
a set of 96 overlapping 20-mer peptides (2-residues frameshift)
synthesized on a cellulose membrane according to the Spot
method [10,17]. The reactivity of the hcTnI peptides was
probed with [125I]cTnC (55.5 nM; 5.3U105 cpm/ml) in the
presence of 3 mM CaCl2. Fig. 1A shows the reactivity pro¢le
obtained after a 3 h radiographic exposure. As expected from
the literature data, cTnC reacted with several hcTnI peptides.
These interactions were abolished by an 150-fold molar excess
of soluble hcTnI (Fig. 1B) and no binding with any peptide
was observed with [125I]IgG, used as an irrelevant protein,
tested under the same conditions (Fig. 1D). From Fig. 1A,
it appears that six groups of peptides were reactive. The ¢rst
one included spot peptides 2^11, the second spot peptides 16^
23, the third spot peptides 60^68, the fourth spot peptides 69^
74, the ¢fth spot peptides 77^81 and the sixth spot peptides
94^96 (Fig. 1A). Table 1 lists the sequences and the reactivity
index of [125I]cTnC reactive peptides. The six interaction sites
were tentatively assigned as follows. Site 1 (hcTnI residues 19^
32) corresponds to the sequence common to the four reactive
peptides from the ¢rst group (spot peptides 7^10); site 1 be-
longs to the N-terminal cardio-speci¢c extension of hcTnI
[13]. Site 2 (hcTnI residues 45^54), was the sequence common
to spot peptides 18^23. Site 3 (hcTnI residues 129^138), was
the sequence common to spot peptides 60^65. Site 4 (hcTnI
residues 145^164) corresponds to a single fairly reactive spot
peptide (number 73). Addition or elimination of residues from
the sequence of this peptide induced an almost complete loss
of reactivity, indicating that all amino acids of peptide 73 were
critical for the interaction. Site 5 (hcTnI residues 161^178)
was established on the basis of the observation that the last
two peptides of the ¢fth set were the most reactive, suggesting
that the presence of residues A161, R162, K177 and K178 was
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important for binding. Spot peptide 80, in the sequence of
which the four residues were present, was more reactive
than the spot peptide 79 which did not contain K177 and
K178. Similarly, spot peptide 82 containing the two K but
not the A161 and R162 showed decreased reactivity in compar-
ison with the spot peptide 81 (Fig. 1A). Site 6 (hcTnI residues
191^210) corresponds to the sequence common to spot pep-
tides 94^96 extended by four residues, because the strongest
reactivity of the spot peptide 96 suggested the critical contri-
bution of residues E209 and S210 for the binding. The Ca2-
dependence of the interaction between TnI and TnC is largely
documented in the literature (a⁄nity of 106 M31 in the ab-
sence of Ca2 and 109 M31 in the presence of Ca2 [18,19]).
The availability of the set of overlapping peptides from the
hcTnI sequence allowed the study of the Ca2-dependence of
cTnC binding to the di¡erent hcTnI regions. Removal of
Ca2 from the binding bu¡er resulted in a marked decrease
in the binding signal for many peptides, except for spot pep-
tides 20^23 (Fig. 1C). These peptides enclosed site 2, which
might correspond to the domain allowing the strong anchor-
age of TnI to TnC, as reported by Farah et al. [20]. The
reactivity of the other ¢ve motifs with [125 I]cTnC was almost
abolished in the presence of EDTA.
3.2. A⁄nity determination of the interaction between hcTnI
peptides and cTnC by BIACORE analysis
Based on the sequence of the peptides used in the Spot
assay, a series of peptides (as described in Section 2) corre-
sponding to the highly reactive sequences of hcTnI and con-
taining each an interaction site was synthesized by conven-
Fig. 1. Reactivity pro¢le of hcTnI peptides assembled by the Spot method with cTnC. The 96 overlapping 20-mer peptides frameshifted by two
residues were synthesized by the Spot method. HcTnI peptide reactivity with (A) [125I]cTnC (55.5 nM, 5.3U105 cpm/ml) in the presence of
3 mM CaCl2, (B) [125I]cTnC (55.5 nM, 5.3U105 cpm/ml) and hcTnI (8.3 WM), (C) [125I]cTnC in the presence of 10 mM EDTA, (D) irrelevant
radiolabelled protein ([125I]IgG, 5U105 cpm/ml) in the presence of 3 mM CaCl2.
Table 1
Identi¢cation of hcTnI regions involved in cTnC interaction
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tional solid phase synthesis and analyzed by real-time inter-
action using BIACORE technology. Increasing concentrations
of the peptides were injected onto the two £owcells, as de-
scribed in Section 2. Typical sensorgrams of the interaction of
two soluble hcTnI peptides (hcTnI [15^34] and hcTnI [39^58])
with immobilized cTnC, in the presence of Ca2 and after
subtraction of the appropriate controls, are shown in Fig.
2A,C). The binding levels (expressed in RU, measured 126 s
after injection) for all the tested peptides are presented in
Table 2. Peptides containing an interaction site in their se-
quence, hcTnI [15^34] (site 1), hcTnI [124^143] (site 3), hcTnI
[145^164] (site 4), hcTnI [159^178] (site 5) and hcTnI [191^
210] (site 6) bound to immobilized cTnC in a dose-dependent
manner. Even at low concentrations, the hcTnI [39^58] pep-
tide, (site 2), bound very strongly to cTnC, suggesting a high
a⁄nity. Only very low binding of this peptide to immobilized
soybean trypsin inhibitor, an irrelevant protein, was observed
(signal6 8 RU at the highest concentration tested). No bind-
ing was detectable with peptides derived from sequences of
hcTnI corresponding to unreactive spot peptides (hcTnI [73^
92], hcTnI [89^108] and hcTnI [109^128]). The deduced equi-
librium dissociation constant (KD) of the interaction with
cTnC was in the 1036 M range for all peptides but two: hcTnI
[145^164] (1.42U1037 M) and hcTnI [39^58] (3.07U1039 M)
(Table 2). The high a⁄nity of peptide hcTnI [39^58] for TnC
was con¢rmed in a separate experiment in which the peptide
was coupled to the CM5 sensor chip and the binding of cTnC
analyzed (KD = 5.72 þ 1.87U1039 M). The binding of hcTnI
[15^34], hcTnI [124^143], hcTnI [145^164], hcTnI [159^178]
and hcTnI [191^210] was not even measurable when the BIA-
CORE experiments were performed in the presence of 10 mM
EDTA (Table 2 and Fig. 2B). This lack of binding to cTnC
Fig. 2. Sensorgrams representing the surface plasmon resonance analysis of the interaction between immobilized cTnC and hcTnI peptides.
A: Binding of hcTnI [15^34] (10, 20, 40 Wg/ml) to cTnC, in the presence of 3 mM CaCl2, (B) in the presence of 10 mM EDTA. C: Binding of
hcTnI [39^58] (2, 5, 10 Wg/ml) to cTnC in the presence of 3 mM CaCl2, (D) in the presence of 10 mM EDTA.
Table 2
Synthetic TnI peptide binding levels and a⁄nities for cTnC measured by surface plasmon resonance
Peptide Binding level at 126 s (RU) KD þ S.D. (M) KD þ S.D. (M)
with Ca2, peptide concentration
(Wg/ml)
with EDTA, peptide concentration
(Wg/ml)
with Ca2 with EDTA
5 10 20 40 5 10 20 40
hcTnI [15^34] NMa 4 12 27 NM 0 0 0 5.17 þ 1.79U1036 NM
hcTnI [15^34 diP] 0 0 1 0 0 0 0 ND NM NM
hcTnI [39^58] 56 55 56 ND 3 15 39 55 3.07 þ 1.40U1039 4.95 þ 0.07U1036
hcTnI [124^143] 7 17 23 79 0 0 0 ND 3.02 þ 1.61U1036 NM
hcTnI [145^164] 98 118 142 NDb 0 8 14 ND 1.42 þ 0.97U1037 NM
hcTnI [159^178] 21 29 43 67 0 1 1 ND 1.42 þ 0.13U1036 NM
hcTnI [191^210] 6 13 25 75 0 1 1 ND 1.69 þ 0.89U1036 NM
hcTnI [73^92] 0 0 0 0 ND ND ND ND NM ND
hcTnI [89^108] 0 0 0 0 0 0 0 0 NM NM
hcTnI [109^128] 0 0 0 0 ND ND ND ND NM ND
Control hcTnI [39^58]c 0 3 5 8 ND ND ND ND NM ND
Each KD value represents the mean þ S.D. of triplicate determinations.
aNot measurable.
bNot determined.
cBinding with soybean trypsin inhibitor.
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con¢rms the Ca2-dependence for sites 1, 3, 4, 5 and 6 of
hcTnI, as observed in the mapping experiments described
above. In the presence of EDTA, only the hcTnI [39^58] pep-
tide was able to interact with cTnC (Fig. 2D). However, its
a⁄nity for the protein was greatly decreased (4.95U1036 M)
as compared with the value measured in the presence of Ca2
(3.07U1039 M) (Table 2). Therefore cTnC interaction of the
site 2 was also Ca2-dependent, but despite a large drop in the
a⁄nity, was still measurable.
3.3. Inhibition of the binding between hcTnI and cTnC by the
synthetic hcTnI peptides
The ability of biotinylated cTnC to bind to immobilized
hcTnI was assessed by ELISA (Fig. 3A). In the presence of
Ca2, cTnC reacted speci¢cally with hcTnI in a dose-depen-
dent manner. Then, competitive binding assays were per-
formed to examine the ability of the synthetic hcTnI peptides
to block the binding of biotinylated cTnC to immobilized
hcTnI (Fig. 3B). The mixture of peptides which contained in
their sequence an interaction site (mixture of peptides hcTnI
[15^34], hcTnI [39^58], hcTnI [124^143], hcTnI [145^164],
hcTnI [159^178], and hcTnI [191^210], designated as POOL)
induced a speci¢c inhibition. An almost complete inhibition
was obtained at 103-fold peptide excess. No inhibition was
observed with the POOL3 (a mixture of non-reactive pep-
tides, i.e. hcTnI [73^92], hcTnI [89^108], and hcTnI [109^
128]). When single peptides were used instead of the mixture,
only the hcTnI [39^58] peptide had an inhibitory e¡ect. The
calculated peptide concentration giving 50% inhibition was 65
nM, in accordance with our observation that hcTnI [39^58]
had a nanomolar a⁄nity for cTnC.
4. Discussion
It is still not precisely known how the troponin components
interact inside the whole troponin complex, but published
models indicate that TnI and TnC interact through multiple
contacts covering a large part of their surface [20^23]. The
aim of our study was to map in a systematic manner all the
hcTnI regions involved in cTnC interactions. We chose the
Spot format which has previously been shown extremely
powerful in mapping protein^protein interaction sites [24].
The study of [125I]cTnC reactivity with 96 overlapping pep-
tides from the hcTnI sequence enabled the assignment of six
speci¢c sites of interaction. We assumed that the strongest
reactive sequences in the Spot analysis contained an interac-
tion site and we synthesized these sequences as soluble pep-
tides. This allowed us to measure, for the ¢rst time in the
Fig. 3. Inhibition by free synthetic hcTnI peptides of the binding of cTnC to hcTnI in a competitive ELISA. HcTnI was coated onto microti-
tration plates. A: CTnC binding pro¢le to immobilized hcTnI or to thyroglobulin (Tg), an irrelevant immobilized protein. B: Binding of 2.7
nM biotinylated cTnC was inhibited by increasing concentrations of either a mixture of synthetic peptides designated by POOL (mixture of
peptides hcTnI [15^34], hcTnI [39^58], hcTnI [124^143], hcTnI [145^164], hcTnI [159^178] and hcTnI [191^210] and by POOL3 (mixture of
control peptides, i.e. hcTnI [73^92], hcTnI [89^108], hcTnI [109^128]) or with isolated hcTnI peptides.
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same set of experiments, an a⁄nity of cTnC with each region
of interaction, as modelled by a 20-mer synthetic peptide. Five
peptides had an a⁄nity in the range of 1036^1037 M, but
peptide hcTnI [39^58] showed a much higher (nanomolar)
a⁄nity. A mixture of the six binding peptides was able to
block the interaction between hcTnI and cTnC. When tested
separately, only the hcTnI [39^58] peptide retained this ability.
We also found that the interaction of cTnC with hcTnI re-
gions 19^32, 45^54, 129^138, 145^164, 161^178 and 191^210
clearly appeared to be Ca2-dependent, whatever the method-
ology used, Spot or BIACORE. The signi¢cance of these re-
sults will now be discussed in the framework of the current
understanding of hcTnI^cTnC interactions.
The ¢rst interaction region was represented by the hcTnI
[15^34] peptide and belonged to the cardiac-speci¢c N-termi-
nal extension. Serines 23 and 24 of the additional N-terminal
segment can be phosphorylated by protein kinase A, produc-
ing a decrease in the Ca2 sensitivity of myo¢brillar Mg2-
dependent ATPase [25]. Little is known about the molecular
mechanism by which diphosphorylated cTnI a¡ects the Ca2
a⁄nity of cTnC. However, an interaction with cTnC could
directly in£uence it [26,27]. The documented antiparallel
mode of interaction between the two proteins suggests that
the N-terminal extension of cTnI interacts with the C-terminal
domain of cTnC. Recently, Gaponenko et al. suggested, from
NMR investigations, that the non-phosphorylated cardiac-
speci¢c N-terminus of hcTnI interacts with the N-terminal
domain of cTnC. This interaction was not observed with the
recombinant fragment (Asp23, Asp24) cTnI 1^80, which
mimics the phosphorylated form of the protein [28]. In our
study, we observed that only one part of the cardiac-speci¢c
extension, containing the two adjacent serines, was able to
bind cTnC. This region might therefore correspond to the
minimal sequence of the extension which could switch be-
tween the N- and C- terminal TnC domains depending on
its phosphorylation state. The hcTnI [15^34] peptide in its
bis-phosphorylated form (hcTnI [15^34 diP]) failed to bind
immobilized cTnC either in the BIACORE or the Spot format
(Table 2 and data not shown). TnI phosphorylation induced a
2.5^3.5-fold decrease in a⁄nity for cTnC [19,27,29,30]. Fur-
thermore, in agreement with our ¢ndings, an NMR study of
the binding of TnI peptide (17^30) to cTnC, indicated an
a⁄nity constant of about 105, lowered by a 100-fold factor
by diphosphorylation [31].
The second interaction site represented by the hcTnI [39^58]
peptide belongs to the region 33^80 which is known to form a
stable binary complex with the C-terminal domain of cTnC
[5,6]. In a completely di¡erent approach, the sequence 44^59
from hcTnI was identi¢ed by the phage-display technology as
corresponding to the minimum region of interaction [32].
However, the a⁄nity of the biotinylated 44^59 peptide mea-
sured by BIACORE was 8.6U1037 M, versus 3.07U1039 M
for the hcTnI [39^58] peptide. This discrepancy could be ex-
plained by the di¡erent BIACORE formats used (bound pep-
tides in the study of Pierce et al., soluble peptides in our case),
and/or by the larger size of our peptide (20 amino acids),
which could then better mimic the interaction site. In the
antiparallel model of TnI^TnC interaction postulated by Far-
ah et al. [20], region 1^40 of the skeletal TnI isoform (equiv-
alent to sequence 33^80 of hcTnI) is strongly anchored to the
C-terminal domain of TnC in the absence and the presence of
Ca2, while the inhibitory and C-terminal region of TnI
switch between actin-tropomyosin in the absence of Ca2
and binding sites of TnC in the presence of Ca2. By analogy
with this model, we propose that the region 45^54 identi¢ed
by the Spot method could correspond to the minimal site of
permanent anchorage of hcTnI to cTnC. This would explain
the binding persistence in the absence of Ca2, observed in the
two tested formats, BIACORE and Spot. HcTnI [39^58] pep-
tide had the strongest a⁄nity for cTnC (3.07U1039 M); it
was also the only peptide able to inhibit the TnI^TnC com-
plex formation with a 65 nM IC50, in keeping with the ob-
servation that the skeletal peptide TnI [1^40] was able to dis-
place TnI from the preformed TnI^TnC complex [33].
Therefore, we postulate that, despite the existence of multiple
cTnC interaction domains on the hcTnI molecule, only the
region of permanent anchorage 45^54 allows stabilization of
the complex.
The third site of interaction (129^138) is part of the inhib-
itory peptide (Ip) (residues 128^148). Our failure to identify
exactly the entire Ip sequence was possibly due to the fact that
the length of the peptides (20 amino acids) used for the Spot
peptide synthesis is shorter than the actual length of Ip (21
amino acids). HcTnI [124^143] peptide binding to the cTnC
was Ca2-dependent, in agreement with literature data show-
ing that the Ip interaction is stronger in presence of Ca2 [23].
Furthermore, hcTnI [124^143] peptide a⁄nity for TnC was
3.02 WM, in the same order of magnitude as that observed
by spectral methods (KA = 5U105 M31, i.e. KD = 2 WM [34]).
The fourth interaction region mimicked by the hcTnI [145^
164] peptide contained the end of the Ip sequence and the
entire sequence (147^163) described by multinuclear multidi-
mensional NMR spectroscopy as binding to the N-terminal
domain of cTnC in the Ca2 saturated state; the cTnI se-
quence 147^163 interacted with the hydrophobic core of
cTnC^Ca2 and stabilized the open conformation of cTnC
[7]. This site is analogous to the sequence 115^131 of the
skeletal TnI isoform whose cTnC binding in a Ca2-depen-
dent manner, as determined by a⁄nity chromatography anal-
ysis, was clearly demonstrated. This ‘second TnC binding site’
is critical to allow TnC to fully and rapidly neutralize the
actomyosin inhibition caused by various peptides [23]. Our
data demonstrate that hcTnI [145^163] binds in a Ca2-de-
pendent manner to cTnC, probably in its N-terminal domain.
A⁄nity measurement by spectral methods for the peptide
147^163 yielded a macroscopic dissociation constant KD of
154 þ 10 WM [7]. This a⁄nity is about six times weaker than
the a⁄nity of skeletal TnI 115^131 for the skeletal cTnC^
Ca2 bound-N-terminal domain [35], and about 1000-fold
weaker than the a⁄nity of hcTnI [145^163] peptide binding
to entire cTnC. This di¡erence in the measured a⁄nity could
result from methodological di¡erences (NMR versus BIA-
CORE) or may be due to the use of one isolated cTnC do-
main in the study of Li et al. [7] and the entire protein in our
case, or, most probably, to the di¡erences in the amino acid
sequences of the two peptides under study: the peptide 147^
163 of Li et al., was lacking three residues (R144, R145 and
V146) which are thought to be important for a⁄nity (see dis-
cussion in the article by Li et al. [7]).
Our results also show that the reactivity of hcTnI region
161^178 with cTnC is Ca2-dependent. A recent study by
Rarick et al. [9] has shown that the C-terminal region of
cTnI is essential for the Ca2-dependent regulation of cardiac
myo¢lament activation. Their data suggest that the inhibitory
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region inhibits about 50% of the ATPase activity, whereas two
other regions (residues 152^188 and 189^199) in mouse cTnI
contribute 25% each. Their results also indicate the presence
of a Ca2-dependent cTnC binding domain within residues
152^188. Therefore residues 164^178, which we mapped,
could correspond more precisely to the second C-terminal
cTnC binding domain implicated in cardiac regulation.
Finally, concerning site 6, our data gave hints as to the
implication of hcTnI region 191^210 in cTnC binding. In
the Olah and Trewelha model [21] and in the cross-linking
study published by Kobayashi [36], most of the skeletal TnI
molecule is involved in TnC interaction, with the exception of
the C-terminal 36 residues. However, it has been found that
recombinant mouse cTnI (1^199), complexed with cTnC, to-
tally restored the Ca2 sensitivity of myo¢brils, whereas the
cTnI (1^188)^cTnC complex only partially restored it and the
cTnI (1^152)^cTnC complex did not restore Ca2-sensitivity
at all [9]. These results indicate that residues 152^199 of cTnI
are essential for Ca2 sensitivity of myo¢brillar ATPase activ-
ity in the heart, probably via an interaction with cTnC [9] ;
our ¢nding of the existence of an interaction site in the 191^
210 residues strengthens this hypothesis. Interestingly, trans-
genic mice expressing TnI (1^193) in their heart were found to
develop ventricular dilatation, diminished contractility and
reduced myo¢lament calcium responsiveness, recapitulating
the phenotype of stunned myocardium [37]. Furthermore, a
product equivalent to rat TnI (1^193) is prominent in the
human post-ischemic myocardium. It has been suggested
that this modi¢cation of the troponin complex may be due
to the lack of the C-terminal region and be directly respon-
sible for the myo¢brillar dysfunction observed in ischemia
[37,38]; our identi¢cation of a new interaction site within
residues 191^210 is in line with this hypothesis.
In conclusion, our systematic approach of the interaction
between hcTnI and cTnC permitted us to map six possible
interaction sites with cTnC. These regions are scattered all
along the hcTnI sequence. A good correlation between our
results and literature data validates the methodological ap-
proach used. The existence of a cTnC interaction site localized
in the N-terminal cardio-speci¢c extension of hcTnI has been
con¢rmed and more precisely identi¢ed. The interaction of
this region with cTnC is largely in£uenced by the phosphor-
ylation state of the protein. We also described residues 39^58
as a high a⁄nity binding site for cTnC. Our data also indi-
cated the occurrence of two Ca2-dependent cTnC, low a⁄n-
ity, binding domains within the C-terminal part of hcTnI,
namely residues 164^178 and 191^210. The latter sequence
may be linked with the cardiac dysfunction observed in
stunned myocardium.
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